Arcutis reports 72% revenue increase for Zoryve in second-quarter 2023 results

Key takeaways:

• Zoryve (roflumilast cream 0.3%) saw a 72% increase in revenue from the first quarter of 2023.
• Arcutis’ total revenue equaled $5.2 million.

Arcutis announced its financial results for the second quarter of 2023, which included a total revenue of $5.2 million and a 72% increase in Zoryve revenue, according to a company press release.

Upon the closing of its second quarter, Arcutis announced that Zoryve, the company’s roflumilast 0.3% cream product for the treatment of plaque psoriasis, produced $4.8 million in product revenue, a 72% increase from the first quarter of the year.

“We continue to execute on our strategy to build the leading innovation-driven dermatology company in the industry,” Frank Watanabe, president and CEO of Arcutis, said in the release. “With our world-class formulation expertise, track record of clinical and regulatory success, and robust commercial infrastructure, topical roflumilast represents a truly unique, de-risked asset, with significant operating leverage and multiple catalysts ahead.”

The company’s continued expansion of Zoryve, including the product’s launch in Canada in June 2023, has resulted in a nearly 40% increase in demand as well as gross-to-net improvement, according to the release.

More than 70,000 prescriptions for Zoryve have been filled by more than 7,500 prescribers since the product’s 2022 launch, the company reports.

Arcutis has also secured high-quality payer coverage for Zoryve for approximately 80% of total commercial lives in the U.S. with more than 90% of those lives having access to Zoryve without prior authorization. According to the release, the company expects the benefits of this coverage to increase gross-to-net improvements in the second half of 2023.